Bvf Partners L P/il - Net Worth and Insider Trading

Bvf Partners L P/il Net Worth

The estimated net worth of Bvf Partners L P/il is at least $1.4 Billion dollars as of 2024-06-21. Bvf Partners L P/il is the 10% Owner of Array BioPharma Inc and owns about 12,965,657 shares of Array BioPharma Inc (ARRY) stock worth over $505 Million. Bvf Partners L P/il is the 10% Owner of Neurocrine Biosciences Inc and owns about 3,527,700 shares of Neurocrine Biosciences Inc (NBIX) stock worth over $473 Million. Bvf Partners L P/il is also the 10% Owner of Arqule Inc and owns about 16,832,292 shares of Arqule Inc (ARQL) stock worth over $337 Million. Besides these, Bvf Partners L P/il also holds ChemoCentryx Inc (CCXI) , Ligand Pharmaceuticals Inc (LGND) , Arena Pharmaceuticals Inc (ARNA) , BioCryst Pharmaceuticals Inc (BCRX) , Rigel Pharmaceuticals Inc (RIGL) , Dynavax Technologies Corp (DVAX) , Curis Inc (CRIS) , Catalyst Biosciences Inc (CBIO) , Capstone Holding Corp (CAPS) , Aeolus Pharmaceuticals Inc (AOLS) , Neurobiological Technologies Inc (NTII) . Details can be seen in Bvf Partners L P/il's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Bvf Partners L P/il has not made any transactions after 2015-06-10 and currently still holds the listed stock(s).

Transaction Summary of Bvf Partners L P/il

To

Bvf Partners L P/il Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Bvf Partners L P/il owns 52 companies in total, including Five Prime Therapeutics Inc (FPRX) , Eledon Pharmaceuticals Inc (ELDN) , and XOMA Corp (XOMA) among others .

Click here to see the complete history of Bvf Partners L P/il’s form 4 insider trades.

Insider Ownership Summary of Bvf Partners L P/il

Ticker Comapny Transaction Date Type of Owner
FPRX Five Prime Therapeutics Inc 2020-10-06 10 percent owner
ELDN Eledon Pharmaceuticals Inc 2020-10-01 10 percent owner
XOMA XOMA Corp 2017-02-10 10 percent owner
LIMIT LIMIT 2020-01-01 10 percent owner
LIMIT LIMIT 2021-06-16 director & other: See Remarks
LIMIT LIMIT 2020-08-18 10 percent owner
LIMIT LIMIT 2020-06-18 10 percent owner
LIMIT LIMIT 2019-06-19 10 percent owner
LIMIT LIMIT 2017-06-09 10 percent owner
LIMIT LIMIT 2019-12-09 10 percent owner
LIMIT LIMIT 2018-11-16 10 percent owner
LIMIT LIMIT 2017-05-01 10 percent owner
LIMIT LIMIT 2017-09-19 10 percent owner
LIMIT LIMIT 2016-11-30 10 percent owner
LIMIT LIMIT 2018-12-04 10 percent owner
LIMIT LIMIT 2017-11-28 10 percent owner
LIMIT LIMIT 2018-05-30 10 percent owner
LIMIT LIMIT 2016-09-08 10 percent owner
LIMIT LIMIT 2017-11-17 10 percent owner
LIMIT LIMIT 2011-09-06 10 percent owner & other: Indirect Beneficial Owner
LIMIT LIMIT 2017-05-08 10 percent owner
LIMIT LIMIT 2016-06-23 10 percent owner
LIMIT LIMIT 2015-06-10 10 percent owner
LIMIT LIMIT 2012-11-16 10 percent owner
LIMIT LIMIT 2014-03-25 10 percent owner & other: Indirect Beneficial Owners
LIMIT LIMIT 2014-03-21 other: See Explanation of Responses
LIMIT LIMIT 2011-10-05 10 percent owner
LIMIT LIMIT 2013-11-19 10 percent owner
LIMIT LIMIT 2011-10-12 10 percent owner & other: Indirect Beneficial Owner
LIMIT LIMIT 2009-12-22 10 percent owner
LIMIT LIMIT 2009-12-18 10 percent owner
LIMIT LIMIT 2009-10-21 10 percent owner
LIMIT LIMIT 2009-09-10 10 percent owner & other: Indirect Beneficial Owners
LIMIT LIMIT 2009-05-15 10 percent owner & other: Group Member
LIMIT LIMIT 2009-02-03 10 percent owner & other: Indirect Beneficial Owners
LIMIT LIMIT 2006-06-06 10 percent owner & other: Indirect Beneficial Owner
LIMIT LIMIT 2006-01-12 10 percent owner & other: Indirect Beneficial Owner
LIMIT LIMIT 2004-07-08 10 percent owner & other: Indirect Beneficial Owner
LIMIT LIMIT 2003-10-27 10 percent owner & other: Indirect Beneficial Owner
LIMIT LIMIT 2017-02-10 10 percent owner
LIMIT LIMIT 2020-12-18 10 percent owner
LIMIT LIMIT 2022-01-25 10 percent owner
LIMIT LIMIT 2021-04-22 director & other: See Remarks
LIMIT LIMIT 2020-11-18 director & 10 percent owner & other: See Remarks
LIMIT LIMIT 2021-12-31 10 percent owner
LIMIT LIMIT 2021-10-28 10 percent owner
LIMIT LIMIT 2022-04-05 director & 10 percent owner
LIMIT LIMIT 2022-06-16 10 percent owner
LIMIT LIMIT 2022-07-11 10 percent owner
LIMIT LIMIT 2022-12-19 10 percent owner
LIMIT LIMIT 2023-02-03 10 percent owner
LIMIT LIMIT 2023-11-02 10 percent owner

Bvf Partners L P/il Latest Holdings Summary

Bvf Partners L P/il currently owns a total of 14 stocks. Among these stocks, Bvf Partners L P/il owns 12,965,657 shares of Array BioPharma Inc (ARRY) as of June 25, 2014, with a value of $505 Million and a weighting of 35.07%. Bvf Partners L P/il owns 3,527,700 shares of Neurocrine Biosciences Inc (NBIX) as of October 12, 2011, with a value of $473 Million and a weighting of 32.84%. Bvf Partners L P/il also owns 16,832,292 shares of Arqule Inc (ARQL) as of April 5, 2010, with a value of $337 Million and a weighting of 23.38%. The other 11 stocks ChemoCentryx Inc (CCXI) , Ligand Pharmaceuticals Inc (LGND) , Arena Pharmaceuticals Inc (ARNA) , BioCryst Pharmaceuticals Inc (BCRX) , Rigel Pharmaceuticals Inc (RIGL) , Dynavax Technologies Corp (DVAX) , Curis Inc (CRIS) , Catalyst Biosciences Inc (CBIO) , Capstone Holding Corp (CAPS) , Aeolus Pharmaceuticals Inc (AOLS) , Neurobiological Technologies Inc (NTII) have a combined weighting of 8.71% among all his current holdings.

Latest Holdings of Bvf Partners L P/il

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ARRY Array BioPharma Inc 2014-06-25 12,965,657 38.95 505,012,340
NBIX Neurocrine Biosciences Inc 2011-10-12 3,527,700 134.07 472,958,739
ARQL Arqule Inc 2010-04-05 16,832,292 20.00 336,645,840
CCXI ChemoCentryx Inc 2015-06-10 1,251,914 51.99 65,087,009
LGND Ligand Pharmaceuticals Inc 2014-03-25 360,300 79.88 28,780,764
ARNA Arena Pharmaceuticals Inc 2004-07-08 99,485 99.99 9,947,505
BCRX BioCryst Pharmaceuticals Inc 2003-10-27 1,455,900 6.14 8,939,226
RIGL Rigel Pharmaceuticals Inc 2013-11-19 6,962,123 0.97 6,724,018
DVAX Dynavax Technologies Corp 2009-09-10 427,885 11.23 4,805,149
CRIS Curis Inc 2009-02-03 142,581 7.96 1,134,945
CBIO Catalyst Biosciences Inc 2012-11-16 3,328 7.67 25,524
CAPS Capstone Holding Corp 2011-09-06 4,610 4.10 18,901
AOLS Aeolus Pharmaceuticals Inc 2005-11-21 1,870,000 0.00 187
NTII Neurobiological Technologies Inc 2009-10-21 331,998 0.00 33

Holding Weightings of Bvf Partners L P/il


Bvf Partners L P/il Form 4 Trading Tracker

According to the SEC Form 4 filings, Bvf Partners L P/il has made a total of 0 transactions in Array BioPharma Inc (ARRY) over the past 5 years. The most-recent trade in Array BioPharma Inc is the sale of 0 shares on June 25, 2014, which brought Bvf Partners L P/il around $0.

According to the SEC Form 4 filings, Bvf Partners L P/il has made a total of 0 transactions in Neurocrine Biosciences Inc (NBIX) over the past 5 years. The most-recent trade in Neurocrine Biosciences Inc is the acquisition of 29,500 shares on October 12, 2011, which cost Bvf Partners L P/il around $175,820.

According to the SEC Form 4 filings, Bvf Partners L P/il has made a total of 0 transactions in Arqule Inc (ARQL) over the past 5 years. The most-recent trade in Arqule Inc is the sale of 603,000 shares on April 5, 2010, which brought Bvf Partners L P/il around $4 Million.

More details on Bvf Partners L P/il's insider transactions can be found in the Insider Trading History of Bvf Partners L P/il table.

Insider Trading History of Bvf Partners L P/il

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Bvf Partners L P/il Trading Performance

GuruFocus tracks the stock performance after each of Bvf Partners L P/il's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Bvf Partners L P/il is 16.03%. GuruFocus also compares Bvf Partners L P/il's trading performance to market benchmark return within the same time period. The performance of stocks bought by Bvf Partners L P/il within 3 months outperforms 43 times out of 88 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Bvf Partners L P/il's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Bvf Partners L P/il

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
33 out of 89 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 15.54 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 15.02 LIMIT LIMIT LIMIT LIMIT LIMIT

Bvf Partners L P/il Ownership Network

Ownership Network List of Bvf Partners L P/il

No Data

Ownership Network Relation of Bvf Partners L P/il

Insider Network Chart

Bvf Partners L P/il Owned Company Details

What does Five Prime Therapeutics Inc do?

Who are the key executives at Five Prime Therapeutics Inc?

Bvf Partners L P/il is the 10 percent owner of Five Prime Therapeutics Inc. Other key executives at Five Prime Therapeutics Inc include 10 percent owner Biotechnology Value Fund L P , 10 percent owner Bvf Inc/il , and other: See Explanation of Responses Biotechnology Value Fund Ii Lp .

Five Prime Therapeutics Inc (FPRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Five Prime Therapeutics Inc (FPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Five Prime Therapeutics Inc (FPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Five Prime Therapeutics Inc (FPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Five Prime Therapeutics Inc Insider Transactions

No Available Data

Bvf Partners L P/il Mailing Address

Above is the net worth, insider trading, and ownership report for Bvf Partners L P/il. You might contact Bvf Partners L P/il via mailing address: 44 Montgomery St., 40th Floor, San Francisco Ca 94104.

Discussions on Bvf Partners L P/il

No discussions yet.